Nura Bio, a San Francisco, CA-based clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, raised more than $140M in Series A funding.
This included the addition of $68M to the initial Series A round of $73M which was announced in 2020.
The round was led by founding investor The Column Group, with participation from continuing investors Samsara Bio Capital and Euclidean Capital, and new investor Sanofi Ventures.
The company intends to use the funds to advance its pipeline of neuroprotective medicines, with its first clinical candidate, NB-4746, recently completing Phase 1 studies in healthy volunteers. Nura Bio plans to initiate a Phase 1b/2 trial in a patient population in 2025.
Led by newly appointed CEO Shilpa Sambashivan, Ph.D., Nura Bio is a clinical-stage biopharmaceutical company developing neuroprotective therapies for the treatment of a broad range of neurological diseases. Its research and early development small molecule pipeline is focused on developing therapies that halt axon degeneration and/or modulate microglial responses to degeneration and injury, with the goal of conferring neuroprotection, across diseases of the central, peripheral, and ocular nervous systems.
NB-4746 targets SARM1, a neuronally enriched nicotinamide adenine dinucleotide (NAD) hydrolase that has emerged as an important axon-intrinsic metabolic sensor and central driver of axon degeneration. Preclinical studies support the potential of NB-4746 to provide broad axonal protection and functional improvement across diseases of the central, peripheral, and ocular nervous systems.
FinSMEs
18/09/2024